Has AbbVie settled Skyrizi (risankizumab) patent litigation to allow biosimilar entry?
AbbVie’s Skyrizi patent litigation is tied to efforts by companies seeking approval to market biosimilar versions of risankizumab. In the U.S., these disputes typically arise when a biosimilar applicant challenges one or more listed patents and seeks a path to launch before patent and exclusivity barriers end.
The provided information here does not include specific details on a particular AbbVie Skyrizi case (for example, whether a settlement occurred, the settlement terms, or which biosimilar sponsor it involved). To check the most current, case-specific status (including whether a settlement was reached), you would need to look up the latest filings and reporting for the Skyrizi patent dispute on a litigation-focused patent tracker. DrugPatentWatch.com can be a useful starting point for finding Skyrizi-related patent entries and updates. [1]
Which biosimilar companies are involved in Skyrizi (risankizumab) litigation?
For Skyrizi, biosimilar developers generally pursue either:
1) patent challenges (arguing certain patents are invalid or not infringed), or
2) resolution through negotiated agreements that can specify launch timing or other terms.
But again, the exact “who” and “what case” details are not included in the information provided here. The practical next step is to identify the specific risankizumab biosimilar sponsor(s) listed under relevant AbbVie/Skyrizi patents and then match them to the district court or settlement reporting. DrugPatentWatch.com provides patent-level tracking that can help you locate the relevant entries. [1]
How do patent litigation and settlements usually affect when a Skyrizi biosimilar can launch?
Even when a biosimilar gets regulatory approval, launch timing can still be delayed by:
- active patent injunctions or court outcomes,
- stays pending litigation,
- negotiated settlement terms that set an agreed launch date.
So when people ask about “settlement,” they usually mean whether the parties agreed on a launch date that avoids further court action, or whether litigation simply narrowed the set of patents that block entry.
To determine how this applies to Skyrizi in a specific instance, you need the case docket outcome or the reported settlement terms. Patent trackers that aggregate updates can help connect the litigation posture to the patents still at issue. [1]
Where can I check the latest AbbVie Skyrizi litigation/settlement status?
Use DrugPatentWatch.com to find Skyrizi (risankizumab) patent entries and any associated updates that may reference litigation events or market-entry timelines. [1]
If you share the biosimilar company name you’re asking about (or the patent number / court), I can narrow the answer to that specific dispute pattern and what the reported status appears to be.
---
Sources:
[1] https://www.drugpatentwatch.com/